Firms eye development of targeted cancer drugs

11/13/2012 | GenomeWeb Daily News (free registration)

AstraZeneca has teamed up with Foundation Medicine to identify genetic mutations in cancer-related tumor genes that may help predict a person's response or resistance to targeted treatments. Under terms of the deal, Foundation will get right of first negotiation to develop diagnostic tests. The deal will allow AstraZeneca to "identify tumor-specific defects and alterations that can be used for patient segmentation," said Susan Galbraith, vice president and head of AstraZeneca's Oncology Innovative Medicines Unit.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA